Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival.

First, despite higher serological CMV risk, we noticed a clear trend of lower CMV incidence in the CMVIg subset (4% vs. 22.2%), which in view of well-known direct and indirect CMV-related harms could have been involved in superior outcome.

also in 19,460 other papers

Only pre-LT elevated lactate level and absence of CMVIg therapy were identified as independent promoters of 3-month mortality, whereas cold ischemia time almost reached statistical significance ( Table 4 ).

also in 378 other papers